Cathy Eng: The Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer
Cathy Eng, Professor of Medicine, Hematology and Oncology, and is the Co-Director of GI Oncology, shared an article on LinkedIn:
“It has been my pleasure to work with Gilead Sciences on our multi-center phase I/II trial in heavily pre-treated metastatic colorectal cancer of anti- CD47 antibody (magrolimab) and EGFR therapy.
Median is equal 5 prior lines of therapy; 2 PRs; KRASwt and KRASmt CRC achieved SD (43.8% and 38.1%, respectively) and half of the patients with KRASwt CRC exhibited disease control rate disease (DCR, 50.0%). The median OS was 9.5 and 7.6 months in patients with KRASwt CRC and KRASmt CRC, respectively.
Absolute pleasure to work with my colleagues: Drs. Lakhani, Philip Agop Philip, Charles Schneider, Benny Johnson, Adel Kardosh, Mark P. Chao, Amita Patnaik, Fadi Shihadeh, Yeonju Lee, Kai Song, Denise Jin, Yanan Huo, Michael Howland, George A. Fisher, J. Randolph Hecht.
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.
Authors: Cathy Eng, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023